Overview: Recent Advances in the Treatment of Heart Failure: Patent Activity in 1992

References

• YUSUF S, Thom T, Ausorr RD: Changes in hypertension treatment and in congestive heart failure mortality in the United States. Hypertension (1989) 12:174–179.
   Google Scholar
• PERSSON H, ERHARDT L: Beta receptor antag-•onists in the treatment of heart failure. Car-diovascular Drugs and Therapy (1991) 5:589–604.
   PubMed Web of Science ®Google Scholar
• A useful review on the effects of beta receptor antagonists in heart failure.
   Google Scholar
• HJALMARSON A, WAAGSTEIN F: New ther- •apeutic strategies in chronic heart failure: challenge of long-term beta-blockade. Eur Heart J. (1991) 12(Suppl F):63–69.
   Google Scholar
• A review covering the use of a wide variety of 13-block-ers in heart failure due to several causes, but in particular idiopathic dilated cardiomyopathy.
   Google Scholar
• ENGLEMEIER RS, O'CONNELL JB, WALSH R, RAD N, SCANLON PJ, GUNNAR RM: Improve-
   Google Scholar
• GILBERTE M, ANDERSONJL, DEITCHMAND,YANOWITFZG, O'CONNELLJ B,R ENLUNDD G,BARTHOLOMEMW, MEALEY Pc, LARRABEEP, BRISTOW MR: Long-term P-blocker vasodilatortherapy improves cardiac functionin idiopathic dilated cardiomyopathy:a double-blind, randomised study of bucindololversus placebo. Am. f. Med. (1990) 881223–229.
   Google Scholar
• COHNJ N, ARCHIBALDD G, ZIESCHES, FRANC 10% JA, HARSTONW E, TRISTANFIE, DUNKMAN WB, JACOBS W, FRANCIS KH: Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N. Engl. J. Med. (1986) 314:1547–1552.
   Google Scholar
• GIRBES ARJ, VAN VELDHUISEN DJ, SMIT Al: Dopamine agonists, a new perspective incardiovascular therapy? Netherlands J. Med. (1991) 39:65–71.
   Google Scholar
• BROWN RA, BROWN RC, HALL JC, DIXON J, FARMER JB, FOULDS RA, INcE F, O'CONNORSE, SIMPSON WT, SMITH GW, SPR1NGTHORPE B, TIN10ER AC: Dopamine analogues in the treatment of heart failure in Third SCI-RSC Medicinal Chemistry Symposium, Cambridge, 15-18th September (1985). Lambert RW (Ed). The Royal Society of Chemistry Special Pub-lication No. 55:169–192.
   Google Scholar
• GARRISON JC, PEACH MJ: Renin and angio-tensin in Goodman and Gilman 's The Pharma- cological Basis of Therapeutics. (1990) Gilman AG, Rail TW, Nies AS, Taylor P (Eds), Perg-amon Press, New York, pp749–763
   Google Scholar
• THE CONSENSUS TRIAL STUDY GROUP: Ef-fects of enalapril on mortality in severe con- gestive heart failure: results of the Coop-erative North Scandinavian Enalapril Sur-vival Study (CONSENSUS). N. EngL J. Med. (1987) 316:1429–1435.
   PubMed Web of Science ®Google Scholar
• THE SOLVD INVESTIGATORS: Effect of enal-april on survival in patients with reduced left ventricular ejection fraction and conges-tive heart failure. N. Engl. J. Med. (1991) 325:293–302.
   PubMed Web of Science ®Google Scholar
• COHN JN, JOHNSON G, ZIESCHE S, COBB F, FRANCIS G, TRISTANI F, SMITH R, DUNKMAN WB, LOEB H, WONG M: A comparison of enalapril with hydralazine-isosorbide dini-trate in the treatment of congestive heart failure. N. Engl. J. Med. (1991) 325:303–310.
   PubMed Web of Science ®Google Scholar
• FELDMAN AM: Can we alter survival in pa-tients with congestive heart failure? JAMA (1992) 267: 1956-1961.
   Google Scholar
• KLEBER FX, NIEMOELLER L, DOERING W: Im-pact of converting enzyme inhibition on pro-v gression of heart failure: results of the Mu-nich Mild Heart Failure trial. Br Heart J (1992) 67:289–296.
   PubMedGoogle Scholar
• KJEKSHUS J, SWEDBERG K, SNAPINN S, FOR THE CONSENSUS TRIAL GROUP: Effects of enalapril on long-term mortality in severe congestive heart failure. Am. J. Cardiol. (1992) 69:103–107.
   PubMed Web of Science ®Google Scholar
• FONAROW GC, CHELIMSKY-FALLICK C, STEV-ENSON LW, Luu M, HAMILTON MA, MORIGUCHI JD, TILLISCH JH, WALDEN JA, ALBANESE E: Effect of direct vasodilation with hy-dralazine versus angiotensin-converting en-zyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J. Am. Coll. Cardiol. (1992) 19:842–850.
   PubMed Web of Science ®Google Scholar
• CHATTERJEE K,DEMARCO P, ROULEAU JL: Vasodilator therapy on chronic congestive heart failure. Am. J. Cardiol. (1988):46A–54A.
   Google Scholar
• PACKER M: The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J. Am. Coll. Car-diol. (1992) 20:248–254.
   PubMed Web of Science ®Google Scholar
• PACKER M: Treatment of chronic heart fail-ure. Lancet (1992) 340:92–95.
   PubMed Web of Science ®Google Scholar
• POOLE-WILSON PA, LINDSAY D: Advances in the treatment of chronic heart failure. Br Med. J. (1992) 304:1069–1070.
   Web of Science ®Google Scholar
• SICA DA: Kinetics of angiotensin-converting enzyme inhibitors in renal failure. J. Car-diovasc. Pharmacol. (1992) 20(Suppl 10):S13–S20.
   Google Scholar
• DUTTA AS: Design and therapeutic potential of 00peptides in Advances in Drug Research. (1991)Testa B (Ed), Academic Press, London, pp145–286.
   Google Scholar
• An excellent review which records the structure-activity investigations which led to the current ACE and renin in-hibitors.
   Google Scholar
• BRUNNER HR, NUSSBERGER J, WAEBER B: Blockade of the renin-angiotensin system in humans: converting enzyme inhibitors, renin inhibitors, and angiotensin II antago-nists. Curr. Opin. Cardiol. (1991) 6:724–730.
   Web of Science ®Google Scholar
• GREENLEE WJ, WEBER AE: Renin Inhibitors. ••Drug News & Perspective (1991) 4:332-339. An excellent review on the development of renin in-hibitors.
   Google Scholar
• KLEINERT HID, ROSENBERG SH, BAKER WR, STEIN HE, KLINGHOFER V, BARLOW J, SPINA K, POLAKOWSKI J, KOVAR P. COHEN J, DENISSEN J: Discovery of a peptide-based renin inhibitor with oral bioavailability and efficacy. Science (1992) 257:1940–1943.
   Google Scholar
• MARTIN SF, AUSTIN RE, OALMANN CJ, BAKERWR, CONDON SL, DELARA E, ROSENBERG SH, SPINA ICP, STEIN HE, COHEN 1, KLEINERT HD: 1,2,3-Trisubstituted cyclopropanes as con-formationally restricted peptide isosteres: application to the design and synthesis of novel renin inhibitors. J. Med. Chem. (1992) 35:1710–1721.
   PubMedGoogle Scholar
• DE LASZLO SE, BUSH BL, DOYLE JJ, GREENLEE W., HANGAUER DG, HALGREN TA, LYNCH RI, SCHORN TW, SIEGL PKS: Synthesis and use of 3-amino-4-phenyl-2-piperidones and 4-amino-2-benzazepin-3-ones as conforms-tionally restricted phenylalanine isosteres in renin inhibitors. J. Med. Chem. (1992) 35:833–846.
   Google Scholar
• OCAIN TD, DEININGER DD, Russo R, SENKO NA, KATZ A, ICITZEN JM, MITCHELL R, OSHIRO G, Russo A, STUPLENSKI R, MCCAULLY RJ: New modified heterocyclic phenylala-nine derivatives. Incorporation into potent inhibitors of human renin. J. Med. Chem. (1992) 35:823–832.
   Google Scholar
• BAKER WR, FUNG AKL, KLEINERT HD, STEIN HE, PLATTNER JJ, ARMIGER Y-L, CONDON SL, COHEN J, EGAN DA, BARLOW JL, VERBURG KM, MARTIN DL, YOUNG GA, POLAKOWSKI JS, BOYD SA, PERUN TJ: Nonpeptide renin inhibitors employing a novel 3-aza(or oxa)-2,4-dialkyl glutartic acid moiety as a P2/P3 amide bond replacement. J. Med. Chem. (1992) 35:1722–1734.
   Google Scholar
• BOYD SA, FUNG AICL, BAKER WR, MANTEL RA, ARMIGER Y-L, STEIN HH, COHEN J, EGAN DA, BARLOW JL, KLINGHOFER V, VERBURG KM, MARTIN DL, YOUNG GA, POLAKOWSKI JS, HOFFMAN DJ, GARREN KW, PERUN Ti, KLEINERT HID: C-Terminal modifications of nonpeptide renin inhibitors: improved oral bioavailability via modifications of physic-ochemical properties. J. Med. Chem. (1992) 35:1735–1746.
   Google Scholar
• PA1T WC, HAMILTON 11W, TAYLOR MD, RYAN MJ, TAYLOR JR DG, CONNOLLY CJC, DOHERTY AM, ICLueranco SR, SIRCAR I, STEINBAUGH BA, BATLEY BL, PAINCHAUD CA, RAPUNDALO ST, MICHNIEWICZ BM, OLSON SC: Structure-activity relationships of a se-ries of 2-amino-4-thiazole-containing renin inhibitors. J. Med. Chem. (1992) 35:2562–2572.
   Google Scholar
• ROBERTS DA, BRADBURY RH, BROWN D, FAULL A, GRIFFITHS D, MAJOR JS, OLDHAM AA, PEARCE RI, RATCLIEth AR, REVILL J, WA'TERSON D: 1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory ac-tivity. 1. Synthesis and biological properties 24. of alkyl alcohol and statine derivatives. J. Med. Chem. (1990) 33:2326-2334. D, WATERSON D: 1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 2. Synthesis, biological properties and molecular modeling of hydroxyethylene isostere derivatives. J. Med. Chem. (1990)
   Google Scholar
• BRADBURY RH, MAJOR JS, OLDHAM AA, RIVET JE, ROBERTSD A, SLATERA M, Tms D, WATERSOND : 1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 2. Synthesis, biological properties and molecular modeling of hydroxyethylene isostere derivatives. J. Med. Chem. (1990
   Google Scholar
• RADDATZ P. JONCZYK A, MINCK K-0, RIPPMANN F, SCHITTENHELM C, SCHMITGES CJ: Renin inhibitors containing new P1-P1' dipeptide mimetics with heterocycles in Pe. J. Med Chem (1992) 35:3525–3536.
   Google Scholar
• KLEEmAN H-W, HErrscH H, HENNING R, KRAMER W, KOCHER W, LERCH U, LINZ W, NICKEL W-U, RUPPERT D, URBACH H, UTZ R,
   Google Scholar
• DHANARAVJ, DEALWISC G, FRAZAO c, BADASS0 M, SlBANDA BL, TICKLE IJ, COOPER JB, DRIESSENH PC, NEWMANM, AGUILARC, WOOD SP, BLUNDELLT L, HOBARTP M, GEOGHEGAN KF, AMMIRATI MJ, DANLEY DE, eO’CONNOR BA, HOOVER DJ: X-ray analysis of peptide-inhibitor complexes define the structural basis of specificity for human and mouse renins. Nature (1992) 357:466–472.
   Google Scholar
• WONG PC, CHIU AT, DUNCIA JV, HERBLIN WF, Smim RD, TIMMERMANS PBMWM: An-giotensin II receptor antagonists and recep-tor subtypes. Trends Endocrin. Metab. (1992) 3:211–217.
   PubMed Web of Science ®Google Scholar
• BLANKLEY CJ, HODGES JC, KLUTCHKO SR, HIMMELSBACH RJ, CHUCHOLOWSKI A, CONN-
   Google Scholar
• FuRuTA H, Guo D-F, INAGAMI T: Molecu-lar cloning and sequencing of the gene en-coding human angiotensin II type 1 recep-tor. Biochem. Biophys. Res. Commun. (1992) 183:8–13.
   PubMed Web of Science ®Google Scholar
• DUNCIA JV, CHIU AT, CARINI DJ, GREGORY class of potent antihypertensives. J. Med. Chem. (1990) 33:1312–1329.
   PubMed Web of Science ®Google Scholar
• CARINI DJ, DUNCIA JV, JOHNSON AL, CHIU AT, PRICE WA, WONG PC, TIMMERMANS PBMWM: Nonpeptide angiotensin II recep-tor antagonists: N-[(benzyloxy)benzyl]imid-azoles and related compounds as potent anti-hypertensives. J. Med. Chem. (1990) 33:1330–1336.
   PubMed Web of Science ®Google Scholar
• CARINI DJ, DUNCIA JV, ALDRICH PE, CHIU AT, JOHNSON AL, PIERCE ME, PRICE WA, SANTELLA III JB, WELLS GJ, WEXLER RR, WONG PC, Yoo S-E, TIMMERMANS PBMWM: Nonpeptide angiotensin II receptor antag-onists: the discovery of a series of N-(biphenylmethyl)imidazoles as potent, orally active antihypertensives../. Med. Chem. (1991) 34:2525–2547.
   PubMed Web of Science ®Google Scholar
• TIMMERMANS PBMWM, WONG PC, CHIU AT, HERBLIN WF: Nonpeptide angiotensin II re-ceptor antagonists. Trends in Pharmacol. Sci-ences (1991) 12:55–62.
   PubMed Web of Science ®Google Scholar
• DE B, WINN M, ZYDOWSKY TM, KERKMAN DJ, DEBERNARDIS JF, LEE J, BUCKNER S, WARNER R, BRUNE M, HANCOCK A, OPGE-NORTH T, MARSH K: Discovery of a novel class of orally active, non-peptide angio-tensin II antagonists. J. Med. Chem. (1992) 35:3714–3717.
   PubMed Web of Science ®Google Scholar
• BRADBURY RH, ALLOTT CP, DENNIS M, FISHER E, MAJOR JS, MASEK BB, OLDHAM AA, PEARCE RJ, RANICINE N, REVILL JM, ROBERTS DA, RUSSELL ST: New nonpeptide angiotensin II receptor antagonists. 2. Syn-thesis, biological properties, and structure-activity relationships of 2-alkyl-4-(biphenyl-ylmethoxy)-quinoline derivatives. J. Med. Chem. (1992) 35:4027–4038.
   Google Scholar
• ALLOTT CP, OLDHAM AA, STEEL JA, WORRALLV, PEARCE RI, ROBERTS DA, RUSSELL ST: Cardiovascular effects of the angiotensin II receptor antagonist ICI D8731 in the dog and marmoset. Br. J. Pharmacol. (1992) 105:Suppl 261P.
   Google Scholar
• ROBERTSON MJ, BARNES JC, DREW GM, CLARK KL, MARSHALL FH, MICHEL A, MIDDLE-MISS D, Ross BC, SCOPES D, DOWLE MD: Pharmacological proffie of GR 117289 in vitro: a novel, potent, and specific non-pep-tide angiotensin ATi receptor antagonist. Br J. Pharmacol. (1992) 107:1173–1180.
   PubMed Web of Science ®Google Scholar
• ATwAL KS, ARMED SZ, BIRD JE, DELANEY CL, DICKINSON KEJ, FERRARA FN, HEDBERG A, MILLER AV, MORELAND S, O'REILLY BC, SCHAEFFER TR, WALDRON TL, WELLER HN: Dihydropyrimidine angiotensin II receptor antagonists. J. Med. Chem. (1992) 35:4751–4763.
   PubMed Web of Science ®Google Scholar
• DICKINSON KEJ, COHEN RB, BIRD JE, WALD-RON TL, SCHAEI+ER TR, MORELAND S, DELANEY CL, SERAFINO R, Poss MA, Gu Z, RYONO DE, POWELL JR: Pharmacological properties of BMS 180,560, an insurmountable angio-tensin II receptor antagonist. Br. J. Pharma-col. (1992) 107:Suppl 465P.
   Google Scholar
• NISATO D, CAZAUBON C, LACOUR C, GOUGAT J, GUIRAUDOU P, BERNHART C, PERREAU P, BRELIERE JC, LE FUR G: Pharmalogical prop-erties of SR 47436, a non-peptidic angio-tensin II receptor antagonist. Br. J. Pharma-col. (1991) 105:Suppl 84P.
   Google Scholar
• ZHANG JS, VAN ZWIETEN PA: Characteri-sation of two novel nonpeptide angiotensin II antagonists. Br J. Pharmacol. (1992) 105:Suppl 85P.
   Google Scholar
• MANTLO NB, CHAKRAVARTY PK, ONDEYKA DL, SIEGL PKS, CHANG RS, LOTTI Vi, FAUST KA, CHEN T-B, SCHORN TW, SWEET CS, EMMERT SE, PATCHETT AA, GREENLEE WJ: Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists. J. Med. Chem. (1991) 34:2919–1922.
   PubMed Web of Science ®Google Scholar
• SAMANEN J, WEINSTOCK J, HEMPEL J, KEENAN RM, HILL DT, OHLSTEIN EH, WEIDLEY EF, AIYAR N, EDWARDS RA: Molecular model of angiotensin II (Ang II) for rational de-sign of small Ang H antagonists with in-creased potency in Peptides: Structures and Biology: Proceedings of the 12th American Peptide Symposium. (1992) Rivier JE, Smith JA (Eds), ESCOM Science Publishers, Leiden, pp386–388.
   Google Scholar
• WEINSTOCK J, KEENAN RM, SAMANEN J, HEMPEL J, FINKELSTEIN JA, FRANZ RG, GArrANoPouLos DE, GIRARD GR, GLEASON JG, HILL DT, MORGAN TM, PEISHOFF CE, AIYAR N, BROOKS DP, FREDRICKSON TA, OHLSTEIN EH, RUFFOLO RR JR, STACK EJ, SULPIZIO AC, WEIDLEY EF, EDWARDS RM: 1-(Carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists. J. Med. Chem. (1991) 34: 1514–1517 .
   PubMedGoogle Scholar
• KEENAN RM, WEINSTOCK .1, FINICELSTEIN JA, FRANZ RG, GATTANoPouLos DE, GIRARD GR, Hill, DT, MORGAN TM, SAMANEN JM, HEMPEL J, EGGLESTON DS, AIYAR N, GRIFFIN E, OHLSTEIN EH, STACK EJ, WEIDLEY EF, EDWARDS R: Imidazole-5-acrylic acids: po-tent nonpeptide angiotensin II receptor an- tagonists designed using a novel peptide pharmacophore model../. Med. Chem. (1992) 35:3858–3872.
   Google Scholar
• UN H-S, RAMPERSAUD AA, ZIMMERMAN K, S'TEINBERG MI, BOYD DB: Nonpeptide angio-tensin H receptor antagonists: synthetic and computational chemistry of N-R442-(2H-tetrazol-5-y0-1-cycloalken-1-yllphenyl]me-thyllimidazole derivatives and their in vitro activity. J. Med. Chem. (1992) 35:2658–2667.
   Google Scholar
• FISCHER TA, ERBEL R, TREESE N: Current status of phosphodiesterase inhibitors in the treatment of heart failure. Drugs (1992) 44:928–945.
   PubMed Web of Science ®Google Scholar
• An excellent review which covers the pharmacological, and clinical aspects of amrinone, milrinone, enoximone and piroximone.
   Google Scholar
• PACKER M, CARVER JR, ROEHEH-ER RJ ET AL., FOR THE PROMISE STUDY RESEARCH GROUP: Effect of oral milrinone on mortality in se-vere chronic heart failure. New EngL J. Med. (1991) 325:1468–1475.
   Google Scholar
• VERNON MW, HEEL RC, BROGDEN RN: Enoxi-mone: a review of its pharmacological properties and therapeutic potential. Drugs (1991) 42:997–1017.
   PubMed Web of Science ®Google Scholar
• URETSKY BF, JEssuP M, KONSTAM MA, DEC W, LEIER CV, ET AL. FOR THE ENOXIMONE MULTICENTRE TRIAL GROUP: Multicentre trial of oral enoximone in patients with moderate to moderately severe congestive heart fail-ure: lack of benefit compared with placebo. Circ (1990) 82:774–780.
   PubMed Web of Science ®Google Scholar